Q3 2020 Sales Performance

Building our oncology commercial capability Improved engagement with HCPs Updated HCP engagement policies to improve how we help prescribers understand new data and clinical experience with our innovative products Attracting and retaining the best sales force talent Competitive sales force incentives in place to recruit, motivate and retain sales teams with the right levels of expertise and experience Seamless execution across functions and in markets Aligned efforts to ensure launch readiness for exciting oncology launches and drive value for patients and shareholders Oncology commercial opportunities in 2020 gsk Zejula approved in US for 1L maintenance in ovarian cancer for all platinum responders; launch ongoing PRIMA presented at ESMO 2019 • Significantly improved PFS in the overall population Belantamab mafodotin (BCMA ADC) relapsed/recurrent Multiple Myeloma (DREAMM-2) approved in US and EU, launch ongoing Strong demand in line with expectations due to high unmet need Study met primary objective and demonstrated clinically meaningful ORR Dostarlimab (PD-1) in recurrent endometrial cancer (GARNET) FDA submission accepted Study met primary objective and demonstrated clinically meaningful ORR and DoR Real time oncology review (RTOR) 33

View entire presentation